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Abstract: Cyclodextrins (CDs) are cyclic oligosaccharides of natural origin that were discovered more
than 100 years ago. The peculiar cone-like conformation of the sugar ring, expressing a lipophilic
cavity and a hydrophilic external surface, allows these substances to spontaneously complex poorly
soluble compounds in an aqueous environment. For more than 50 years, these substances have
found applicability in the pharmaceutical and food industries as solubilizing agents for poorly
soluble chemical entities. Nowadays, several research groups all over the world are investigating
their potential as active pharmaceutical ingredients (APIs) for the treatment of several illnesses
(e.g., hypercholesterolemia, cancer, Niemann-Pick Type C disease). The aim of this review is to briefly
retrace cyclodextrins’ legacy as complexing agents and describe the current and future prospects of
this class of chemical entities in pharmaceutics as new APIs.
Keywords: cyclodextrins; inclusion complexes; solubilizing agents; cytotoxic activity;
hypocholesterolemic agents; Niemann-Pick Type C disease treatment
1. Cyclodextrin Types and Characteristics
Cyclodextrins (CDs) are chemical entities of natural origin, which are derived from bacterial
degradation of starch through the metabolic action of cyclodextrin glycosyl transferase enzyme
(GCTase). This peculiar enzyme is present in several species of alkalophilic bacillus species
(e.g., Bacillus macerans [1]) and it is capable of catalyzing the synthesis of cyclic oligosaccharides,
starting from amylose. The general structure of CDs is based on α-D-glucopyranose units linked
1→ 4, as in amylose. Three ring-types are common, where alpha-cyclodextrin (αCD) is composed
of six, beta-cyclodextrin of seven (βCD), and gamma-cyclodextrin of eight glucose units (γCD).
All CDs are shaped as trunked cones (Figure 1A), expressing a hydrophobic inner cavity and
an external hydrophilic surface. Even though the chemical structure of CDs may appear rather
simple, the complete characterization and understanding of CDs chemical properties and geometrical
three-dimensional conformations was a research enterprise, which required more than half a century
to be completed [2]. The first isolation of cyclodextrins was made in 1891 by Antoine Villiers,
but it took more than 50 years to obtain the correct characterization of cyclohexaamylose (αCD)
and cycloheptaamylose (βCD) molecular weighs [3]. The basic physicochemical characteristics of α-,
β-, and γCDs—including a detailed description of cavity sizes and, for the first time, inclusion of
complex formation tendency—was first published in 1954 by Friedrich Cramer [2,4]. Subsequently,
Pulley and French [5] discovered bigger cyclodextrins composed of 9 (δCD), 10 (εCD), and 11 (ζCD)
glucose units (Figure 1C). At present, cyclodextrins containing up to 31 glucose units have been
purified and characterized and the existence of even larger cyclodextrins containing up to several
hundreds of glycosyl units have been reported [6]. The most important physicochemical properties of
α-, β-, and γCDs (most relevant CDs) are reported in Table 1.
Molecules 2017, 22, 1; doi:10.3390/molecules22010001 www.mdpi.com/journal/molecules
Molecules 2017, 22, 1 2 of 14
Molecules 2016, 21, 1751 2 of 14 
 
 
Figure 1. Front side prospect (A); top prospect (B); nomenclature and chemical characteristics (C) of 
most common cyclodextrins. The blue oxygens represent the etheric bonds 1–4 (inter-monomeric 
bonds), whereas, the red oxygens represents pyranose ether bonds 1–5 (intra-monomeric bonds). The 
green lines represent the intramolecular H-bonds forming in βCD when no substituent groups are 
present (R: -H). 
As it can be seen, aqueous solubility of cyclic saccharides is much lower in comparison to similar 
acyclic sugar molecules. The reason of that is found in the high energy of crystal lattice owned by 
cyclic saccharides when in a solid state. Among the three most investigated CDs, βCD has the lowest 
solubility in water (approx. 0.016 M at 25 °C), followed by αCD (0.12 M) and γCD (0.17 M) [7]. It is 
quite interesting to see that βCD shows significantly less water solubility with respects to similar 
cyclic saccharides. This phenomenon is connected to intramolecular hydrogen bond formation 
between the hydroxyl groups of neighboring glucose units [8], as shown in Figure 1. This is reflected 
in the higher Gibbs free energy of dissolution owned by βCD in comparison to others (Table 1). Even 
though the hepta-pyranose ring results in poor aqueous solubility, the cavity diameter (6 to 6.5 Å) is 
of optimal size to accommodate a vast majority of chemical entities [9]. To increase the poor aqueous 
solubility of βCD, several derivatives have been synthetized substituting hydroxyl groups with other 
hydrophilic moieties such as sulfobutyl ether- (SBEβCD) and hydroxypropyl groups (HPβCD) 
(Figure 1C). The introduction of methyl groups (MβCD) also proved to be very efficient in increasing 
aqueous solubility of βCD due to the breakage of intramolecular hydrogen bonds [10]. Recently, 
polymeric derivatives of βCDs such as polyethylene glycol- (βCD-PEG) and dextran- βCD (βCD-
dextran) have been developed to achieve higher aqueous solubility [11,12]. 
Table 1. Some physicochemical properties of the most relevant CDs (α-, β-, and γCD) at 25 °C. 
 αCD βCD γCD 
Cavity diameter (Å) ≈5.2 ≈6.6 ≈8.4 
Cavity volume (Å3) 100 160 250 
Water molecules in the cavity (nr) 2.5 5.0 8.5 
Aqueous solubility (M) 0.12 0.016 0.17 
Gibbs free energy of dissolution (kJ/mol) 15 20 14 
  
Figure 1. Front side prospect (A); top prospect (B); nomenclature and chemical characteristics (C)
of most co mon cyclodextrins. The blue oxygens represent the etheric bonds 1–4 (inter- ono eric
bon s), hereas, the red oxygens represents pyranose ether bonds 1–5 (intra-monomeric bonds).
The green lines represent the intramolecular H-bonds forming in βCD when no substituent gro s are
rese t ( : - ).
Table 1. Some physicochemical properties of the most rel vant CDs (α-, β-, a d γCD) at 25 ◦C.
αCD βCD γCD
Cavity diameter (Å) ≈5.2 ≈6.6 ≈8.4
Cavity volume (Å3) 100 160 250
Water molecules in the cavity (nr) 2.5 5.0 8.5
Aqueous solubility (M) 0.12 0.016 0.17
Gibbs free energy of dissolution (kJ/mol) 15 20 14
As it can be seen, aqueous solubility of cyclic saccharides is much lower in comparison to similar
acyclic sugar molecules. The reason of that is found in the high energy of crystal lattice owned by
cyclic saccharides when in a solid state. Among the three most investigated CDs, βCD has the lowest
solubility in water (approx. 0.016 M at 25 ◦C), followed by αCD (0.12 M) and γCD (0.17 M) [7]. It is
quite interesting to see that βCD shows significantly less water solubility with respects to similar cyclic
saccharides. This phenomenon is connected to intramolecular hydrogen bond formation between the
hydroxyl groups of neighboring glucose units [8], as shown in Figure 1. This is reflected in the higher
Gibbs free energy of dissolution owned by βCD in comparison to others (Table 1). Even though the
hepta-pyranose ring results in poor aqueous solubility, the cavity diameter (6 to 6.5 Å) is of optimal size
to accommodate a vast majority of chemical entities [9]. To increase the poor aqueous solubility of βCD,
several derivatives have been synthetized substituting hydroxyl groups with other hydrophilic moieties
such as sulfobutyl ether- (SBEβCD) and hydroxypropyl groups (HPβCD) (Figure 1C). The introduction
of methyl groups (MβCD) also proved to be very efficient in increasing aqueous solubility of βCD due
to the breakage of intramolecular hydrogen bonds [10]. Recently, polymeric derivatives of βCDs such
as polyethylene glycol- (βCD-PEG) and dextran- βCD (βCD-dextran) have been developed to achieve
higher aqueous solubility [11,12].
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2. Inclusion Complex Formation and Its Investigation
When cyclodextrins (the ligand, L) are in aqueous solution together with compatible molecules
(the substrate, S), they will spontaneously interact forming an inclusion complex (Figure 2).
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Figure 2. Schematic representation of the inclusion mechanism of complexation between CD (the 
ligand, L) and a small molecule (the substrate, S) in the case of 1:1 stoichiometry (molar ratio). The 
depth (a) that the substrate molecule can reach in the CD cavity varies according to the substrate 
physicochemical properties and CD steric hindrance. 
If the stoichiometry of the complexation is 1:1 (Figure 2), the complexation equilibrium and its 
stability constant are expressed as: 
 (1) 
 (2) 
where SL represents the complex formed between substrate and ligand and K11 the stability constant 
of the complex (generally expressed in M−1). 
From the thermodynamic point of view, the Gibbs free energy (ΔG0) of complexation results are: Δ Δ Δ  (3) 
where R is the gas constant, T is the absolute temperature, ΔH0 is the standard enthalpy of 
complexation, and ΔS0 is the standard entropy of complexation. The driving forces of spontaneous 
complexation are primarily the formation of non-ionic interaction (e.g., van der Waals interactions, 
hydrogen bonds formation) between the CD cavity and the binding site of the substrate (resulting in 
negative standard enthalpy) and the solvent effect (resulting in either positive or negative standard 
entropy) [13]. For the three most common CDs, K11 values vary from 0.1 M−1 for very weak 
interactions, up to 1,000,000 M−1 for very stable complexations. Moreover, α-, β-, and γCDs appear to 
be quite alike in their complexation abilities [14]. Unfortunately, standard βCD is of poor aqueous 
solubility (Table 1). Therefore, its direct usability is limited. Common techniques used to investigate 
the stability of the complex cyclodextrin-substrate are calorimetric analysis [15,16], nuclear magnetic 
resonance (NMR) [17,18], X-ray diffraction [19], and computational modelling [20]. An alternative 
classical method widely used to investigate the efficiency of CDs complexation with APIs is phase-
solubility study [21,22]. This method is based on the paradigm that, if the CD is complexing a ligand 
in solution, this will result in solubilization of the API (i.e., higher apparent aqueous solubility of the 
substrate). Figure 3 shows all different types of phase solubility diagrams obtainable for CD complexation 
and solubilization of substrates. 
When there is a linear dependence between the substrate (i.e., API molecule) concentration and 
the ligand (i.e., CD) concentration, the graphs are generally defined as AL type [22]. In this case, the 
relation between concentration of CD and the API results in a linear regression. From this type of 
graph, knowing the thermodynamic solubility of the substrate (S0) and the slope of the linear 
regression, it is possible to estimate the equilibrium constant employing Equation (4) [13]: 
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physicoche ical properties and C steric hindrance.
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where SL represents the complex formed between substrate and ligand and K11 the stability constant
of the complex (generally expressed in M−1).
From the thermodynamic point of view, the Gibbs free energy (∆G0) of complexation results are:
∆G0 = −RTlnK11 = ∆H0 − T∆S0 (3)
where R is the gas constant, T is the absolute temperature, ∆H0 is the standard enthalpy of
complexation, and ∆S0 is the standard entropy of complexation. The driving forces of spontaneous
complexation are primarily the formation of non-ionic interaction (e.g., van der Waals interactions,
hydrogen bonds formation) between the CD cavity and the binding site of the substrate (resulting in
negative standard enthalpy) and the solvent effect (resulting in either positive or negative standard
entropy) [13]. For the three most common CDs, K11 values vary from 0.1 M−1 for very weak interactions,
up to 1,000,000 M−1 for very stable complexations. Moreover, α-, β-, and γCDs appear to be quite
alike in their complexation abilities [14]. Unfortunately, standard βCD is of poor aqueous solubility
(Table 1). Therefore, its direct usability is limited. Common techniques used to investigate the stability
of the complex cyclodextrin-substrate are calorimetric analysis [15,16], nuclear magnetic resonance
(NMR) [17,18], X-ray diffraction [19], and computational modelling [20]. An alternative classical
method widely used to investigate the efficiency of CDs complexation with APIs is phase-solubility
study [21,22]. This method is based on the paradigm that, if the CD is complexing a ligand in solution,
this will result in solubilization of the API (i.e., higher apparent aqueous solubility of the substrate).
Figure 3 shows all different types of phase solubility diagrams obtainable for CD complexation and
solubilization of substrates.
Molecules 2017, 22, 1 4 of 14
Molecules 2016, 21, 1751 4 of 14 
 
: 1  (4) 
Phase-solubility study is a very efficient method for the evaluation of cyclodextrin solubilization 
of a substrate (i.e., increasing of apparent solubility of an API, Figure 3) but it shows limitations in 
stability constant determination [23]. Moreover, the choice of the condition of the aqueous media of 
complexation (e.g., pH, tonicity) is crucial for a correct estimation of K1:1 with this technique. For 
instance: in Figure 4, the phase-solubility diagram of ibuprofen (IBU, API commonly used as model 
drug for complexation studies [17,24,25]) in the presence of βCD is reported as an example. From 
Figure 4, it is clear that pH of the experiment has a huge impact on the phase-solubility profile of IBU 
and, consequently, on the equilibrium constant. In the case of IBU at pH 3.8 (Figure 4A), the calculated 
K1:1 results are 7.9 × 103 M−1 (in good agreement with ITC data reported in the literature [17]). 
However, for the same complexation in neutral pH (Figure 4B), the equilibrium constant results 
calculated from the phase-solubility diagram are almost three orders of magnitude lower. Deviation 
from the linearity in a phase-solubility diagram indicates a deviation from a 1:1 stoichiometry of 
reaction. The deviation from linearity can be positive (AP) or negative (AN) (Figure 3). A positive or 
negative deviation form linearity implies that the molar ratio between ligand and substrate (CD and 
drug respectively) is not 1:1 [10]. 
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Phase-solubility study is a very efficient method for the evaluation of cyclodextrin solubilization
of a substrate (i.e., increasing of apparent solubility of an API, Figure 3) but it shows limitations in
stability constant determination [23]. Moreover, the choice of the condition of the aqueous media
of complexation (e.g., pH, tonicity) is crucial for a correct estimation of K1:1 with this technique.
For instance: in Figure 4, the phase-solubility diagram of ibuprofen (IBU, API commonly used as
model drug for complexation studies [17,24,25]) in the presence of βCD is reported as an example.
From Figure 4, it is clear that pH of the experiment has a huge impact on the phase-solubility profile
of IBU and, consequently, on the equilibrium constant. In the case of IBU at pH 3.8 (Figure 4A),
the calculated K1:1 results are 7.9 × 103 M−1 (in good agreement with ITC data reported in the
literature [17]). However, for the same complexation in neutral pH (Figure 4B), the equilibrium
constant results calculated from the phase-solubility diagram are almost three orders of magnitude
lower. Deviation from the linearity in a phase-solubility diagram indicates a deviation from a
1:1 stoichiometry of reaction. The deviation from linearity can be positive (AP) or negative (AN)
(Figure 3). A positive or negative deviation form linearity implies that the molar ratio between ligand
and substrate (CD and drug respectively) is not 1:1 [10].
In this case, it is very difficult to predict from these diagrams the real stoichiometry of CD-drug
complex formation. Positive deviation has been described by Loftsson et al. [26] to be primarily
associated with formation of water-soluble aggregates through non-inclusion complexation with a
stoichiometry drug/CD from 1:2 to 1:3. Negative deviation from linearity is in most cases very difficult
to describe stoichiometrically. Quoting Nicol at al. [27], studies on non-linear drug solubility based on
the many-body interaction theory “AP behavior is due to the overriding drug-CD interaction, whereas
AN results from the overriding drug-induced weakening of CD-CD interactions”. If there is no increase
Molecules 2017, 22, 1 5 of 14
or an increase followed by a drastic decrease of the substrate, solubility is measured with increasing
concentration of CD, this generally indicates precipitation of the complex CD-drug. These diagrams
are generally defined as B types (BS and BI, Figure 3) [13]. It has been reported that complexation
efficiency of CDs might, in some cases, be negatively influenced by the presence of substituent groups
anchored to the cavity entrance [17]. This phenomenon is attributed to steric hindrance that reduces
the depth that the substrate molecule can reach in the CD cavity (Figure 5, [28]).
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obtained by typing the generic names of the most common CDs as keywords. This diagram clearly 
shows that βCD (and its derivatives) are by far the most studied cyclic oligosaccharides, followed by 
αCD and γCD. Figure 6 also shows that larger cyclodextrins are currently very poorly studied. 
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The ability of CDs, and especially the strong ability of βCDs in forming stable inclusion complexes 
with poorly soluble and lipophilic moieties in aqueous environments, was immediately recognized 
to have big potentials in drug development and food industry. Cyclodextrins were first employed in 
the food industry in the 1970s, and from that time they have been mostly used as food additives for 
carrying food-related lipophiles (e.g., vitamins, aromas, and colorants) and for inhibiting light/heat 
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3. Food and Drugs Relevance of CDs
The interest of pharmaceutical research and food industry has been mostly pointed to
hepta-pyranose ring types and, to a lower extent, α- and γCDs. Figure 6 reports the number
of search results obtained by typing the generic names of the most common CDs as keywords.
This diagram clearly shows that βCD (and its derivatives) are by far the most studied cyclic
oligosaccharides, followed by αCD and γCD. Figure 6 also shows that larger cyclodextrins are currently
very poorly studied.
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The ability of CDs, and especially the strong ability of βCDs in forming stable inclusion complexes
with poorly soluble and lipophilic moieties in aqueous environments, was immediately recognized to
have big potentials in drug development and food industry. Cyclodextrins were first employed in the
food industry in the 1970s, and from that time they have been mostly used as food additives for carrying
food-related lipophiles (e.g., vitamins, aromas, and colorants) and for inhibiting light/heat mediated
food degradation [29]. βCD was found suitable as a cholesterol-reducing agent in food of animal origin
such as mink and egg [30,31]. The first pharmaceutical patent related to CDs and pharmaceutical
applicability as complexing agents is dated 1953 [32]. Cyclodextrins are employed in pharmaceutical
products primarily to increase water solubility of poorly soluble APIs, in order to enhance their
bioavailabilities. Pharmaceutical products containing CDs comprise nasal spray, oral solutions, solid
dosage forms, ocular and dermal formulations, suppositories, and parenteral solutions [33]. Currently,
more than 40 pharmaceutical products containing cyclodextrin are available in the market worldwide,
and the vast majority of them utilize βCD and its derivatives of higher water solubility such as HPβCD,
MβCD, and SBEβCD [34]. Most of the βCD are approved from the European Medical Agency (EMA)
for all administration pathways besides parenteral administration where only HPβCD and SBEβCD
are approved [33]. MβCD application is limited to nasal and ocular administration due to side effects
such as hemolysis. Even though MβCD has thermodynamically favorable complexation potentials
for phospholipids [35], it is assumed that the hemolytic effect is primarily related to cholesterol
segregation and depletion from plasma membranes of erythrocytes [36,37]. It is largely unknown,
but CDs were first employed as therapeutic agents almost 30 years ago. In fact, in 1987 Carpenter
and co-workers administered HPβCD to two siblings affected by an acute intoxication from retinoids
(hypervitaminosis A). In this trial experiment, HPβCD proved to increase the urinary excretion of
vitamin A, helping in the treatment of the acute symptoms of the intoxication [38].
The aim of the following sections is to present the reported interactions of βCDs with some
biological substrates and the consequent in vivo and in vitro effects induced by these interactions.
These effects (poorly highlighted until now) might lead to the development of βCDs as APIs.
4. Interaction of Cyclodextrins with Biologically Relevant Substrates
4.1. Interaction with Cholesterol and Lipids
The interaction of lipids and cholesterol with cyclodextrins has been extensively investigated in the
last two decades. Loftsson and co-workers investigated the complexation reaction between cholesterol
and different types of βCD in aqueous dispersion by phase-solubility diagrams [26]. It was shown
that cholesterol had the highest affinity for the most lipophilic βCD (methylated one), but the lowest
affinity for the very hydrophilic HPβCD and charged βCD (i.e., SBEβCD). From the phase-solubility
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diagrams of uncharged cyclodextrins, they estimated the formation of 1:2 drug/cyclodextrin complexes.
These findings were later confirmed from Nishijo and co-workers [39]. In their study, they
characterized the aqueous complex between cholesterol and different sugar rings of different cavity
sizes (α-, β-, and γCD) using phase-solubility studies as well as NMR spectroscopy. Their results
showed that only the methylated derivatives of βCD (MβCDs) were able to complex and solubilize
cholesterol in an aqueous environment, whereas native βCD, αCD, and γCD cyclodextrin were
not. More recent studies elucidated that native βCD is also capable of complexing and solubilizing
cholesterol, but the effect is not measurable through phase-solubility study at room temperature [40]
because of the precipitation of the poorly soluble βCD-cholesterol conjugates. This observation
was confirmed by molecular dynamic simulations studies [41]. Highly hydrophilic polymeric
derivative of standard native βCD (i.e., dextran derivative, βCD-dextran) showed comparable
cholesterol-solubilization efficiency to MβCD [42]. For the same polymers, it was proven by isothermal
titration calorimetry that the complexation efficiency of the βCD units was not negatively affected
by the anchorage to the polymeric chain [43]. Recently, the ability of different types of βCD to
deplete cholesterol (and cholesteryl esters) from phospholipid bilayers has been proven. Stelzl and
co-workers [42] showed that cholesterol depletion from giant unilamellar vesicles (GUV) composed of
phosphatidylcholine (PC) and cholesterol was a favorable process that spontaneously took place when
the lipid bilayers were exposed to different types of βCD (primarily MβCD, βCD-dextran and, to a
smaller extent, HPβCD) in a water environment. A similar study conducted by Litz and co-workers
showed by fluorescence spectroscopy that cholesterol removal from GUVs was extremely fast (in the
order of milliseconds), and it produced the formation of extended holes in the lipid bilayers (in vesicles
composed by both saturated and unsaturated phospholipids) [44]. MβCD was found to have a strong
and thermodynamically favorable inclusion affinity also for the phospholipids composing the vesicle
bilayer (1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine) [35]. Interestingly, Ao and co-workers [45]
recently have shown that hydrophobic derivatives of βCDs (i.e., MβCD) are capable of disassembling
low-density lipoprotein aggregates (LDL) by lipids (both phospholipids and cholesterol) segregation
and they are significantly reducing the oxidation tendency of LDL (widely accepted as the key trigger
of atherosclerosis).
4.2. Interaction with Proteins
Cyclodextrins have been found to be capable of interacting not only with lipophilic moieties
but also with hydrophilic biological macromolecules such as proteins, effecting their stability and
aggregation tendency [46]. Differential scanning calorimetry (DSC) of a range of proteins has
shown that α- and βCDs can reduce the mean unfolding temperature of some biologically relevant
proteins (e.g., lysozyme, ribonuclease A, ubiquitin, and yeast phosphoglycerate kinase). It has been
suggested that this phenomenon is related to the inclusion of aromatic portions of some amino acids
(e.g., tryptophan) from CDs, effecting protein stability [47]. The spontaneous inclusion tendency
of βCDs of amino acids containing aromatic groups was later confirmed by a combined NMR and
molecular docking approach [48]. Other studies showed that both MβCD and HPβCD were capable
of forming spontaneous complexes with a portion of insulin, inducing a stabilizing/protecting effect
in different aqueous environments and temperatures [49,50]. This stabilization effect also prevented
aggregation of insulin molecules in solution. Another very interesting interaction that has been
described is the interaction between βCDs and β-amyloid peptide [51]. B-amyloid is the major
constituent of the plaques forming in the human brain that induce Alzheimer’s disease (AD). It has
been shown that βCDs can form inclusion complexes with portions of the peptide (where tyrosine
and phenylalanine amino acids are located) [52]. This interaction sensibly reduces the aggregation
tendency of this peptide in aqueous solution.
All these spontaneous interactions between CDs and biologically relevant substrates induce
evident effects when cyclodextrin is applied in vitro or administered in vivo.
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5. Effect of Cyclodextrin In Vitro
Cholesterol is an essential component of plasma cell membranes. It is fundamental in keeping
barrier integrity and its involvement in the growth and proliferation of cells has been described.
In 1982, Irie and co-workers reported a lytic and shape-changing effect induced on human erythrocytes
by some types of CD derivatives and in particular HPβCDs [53]. They observed a change in surface
tension in the plasma membrane and they suggested that this phenomenon was due to segregation of
important components of cell barriers (lipids and cholesterol in particular). In 1994, Learoy-Lechat
and co-workers identified that, when eukaryotic cell lines (such as erythrocytes and murine leukemic
cells P388) were incubated with significant amount of different α-, β-, and γCD (unmodified and
hydroxypropylated), their viability was compromised [54]. The in vitro cytotoxicity of CDs was
ranked as βCD > αCD > γCD (the same ranking was found for the hydroxypropylated derivatives).
In accordance with Irie and co-workers, they also suggested that segregation of important components
of cell membranes from CDs (in particular cholesterol) was the key factor in triggering hemolysis.
More recently, an effect of CDs on plasma fibrinogen and a consequent effect on coagulation has also
been described [55].
Another study performed by Kiss and co-workers [36] (focused primarily on both neutral
and ionic derivatives of βCD) demonstrated a solid correlation between βCDs cytotoxicity and
cholesterol segregation ability. In this regard, it has been shown that the depletion of cholesterol
from cell membranes can lead to spontaneous activation of apoptotic/necrotic mechanisms [56–59].
However, it is still unclear which cellular mechanism promotes cell death after cholesterol depletion.
One possible mechanism might be related to the perturbation of cell raft domains and the consequent
alteration of the cascade of intramolecular signals regulated by them. In fact, the lipid raft domains
of plasma membranes control several membrane receptors and regulate a number of intracellular
signaling pathways [60]. Membrane lipid rafts have been implicated in the regulation of malignant cell
proliferation, differentiation, apoptosis, and migration [61,62], suggesting that the alteration of these
domains might lead to inhibition of metastatic cells growth/migration, also inducing cell death [63].
As mentioned earlier, hepta-sucrose rings showed ability in interaction with peptides and proteins.
A recent study from Ren and co-workers [64] has shown that HPβCD owns strong inhibitory effect
on the aggregation of amyloid-β peptides. They also have shown that administration of HPβCD
on compromised neuroblastoma cells (i.e., previously exposed to β-amyloid peptide) significantly
increases cell viability.
6. Potentials of Cyclodextrins in Therapy: In Vivo and in Human Evidence
6.1. Cyclodextrin Potentials on Atherosclerosis and Dyslipidemia Treatment
One of the predominant pharmacological effects that is reported in the literature for βCDs
derivatives is their positive pharmacological activity on the cardiovascular system. In 1992. Irie and
co-workers administered intravenous (IV) HPβCD to hyperlipidemic rabbit. They demonstrated
a decrease in blood cholesterol levels after a single administration [53]. Sustained parenteral
administration of HPβCD in animals increased cholesterol concentration in urines, inducing a positive
effect on atherosclerotic plaques. In their 1995 study, Favier and co-workers [65] orally administered to
male Wistar rats daily doses of βCD through animals’ regular food. Amazingly, they demonstrated
that βCD acted as a very efficient hypocholesterolemic agent. They verified that the blood cholesterol
content, as well as the concentrations of low density lipoprotein protein (LDL) and very low density
lipoprotein (VLDL), were significantly reduced when βCD were administered through the food.
Whereas concentration of high density lipoprotein (HDL) was less effected. A significant reduction
in lipoprotein triglycerides content was also demonstrated, but predominantly when βCD were
administered through a low-fat dietary regime.
Rivers and co-worker focused their attention on hypoxia and ischemia, demonstrating that the
administration of HPβCD to rats after 30 min from the appearance of hypoxia/ischemia symptoms
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significantly reduced brain injuries [66]. The authors proposed HPβCD as a possible new treatment
of cerebral ischemic injury. More recently, it has been shown that intraperitoneal administration
of aqueous infusion of KLEPTOSE® CRYSMEB (commercial name of MβCD from Rochètte Freres,
Lestrem, France) were able to efficiently reduce atherosclerosis in ApoE−/− male mice (class of mice
often employed as in vivo models for atherosclerosis). Similar results were obtained by Zimmer and
co-workers [67] on the same animal model but employing the more hydrophilic and FDA/EMA
approved HPβCD. Both studies agreed that the mechanism by which βCD derivatives develop
regression in atherosclerosis was a combination of alteration of lipid profile (i.e., hypocholesterolemic
effect) and by influencing the inflammatory response that triggers atherosclerotic plaque formation
(i.e., interaction with macrophages and lymphocytes). Zimmer and co-workers actually proposed
HPβCD as a new treatment for atherosclerosis.
6.2. Cyclodextrins Potentials in Chemotherapy
As described previously, βCD and its derivatives of higher water solubility (i.e., MβCD and
HPβCD) have shown interesting cytostatic/cytotoxic activity cholesterol-depletion mediated on
different cell lines. However, just a handful of studies have been conducted to verify the potential of
βCDs as APIs in chemotherapy. In 1998, Grosse and co-workers [68] demonstrated that intraperitoneal
(IP) injections of aqueous solution of MβCD significantly inhibited the growth of human solid tumors
implanted on mice (breast cancer and ovarian carcinoma cell lines). The antiproliferative effect of
MβCD was comparable to the one measured for doxorubicin. Intratumoral (IT) injection of MβCD
aqueous solutions resulted in an even higher antiproliferative effect [58]. More recently, Mohammed
and co-workers proved that administration of tamoxifen in combination with MβCD significantly
diminished (approx. 75% in normal diet fed animals) the size and weight of solid tumors in mice [69].
They also found out that, when animals were feed with a cholesterol rich dietary regime, no significant
reduction in the size of the solid tumor was measurable when MβCD and/or tamoxifen where
administered. This fact clearly indicates that cholesterol plays a fundamental role in tumor growth and
that MβCD activity is almost certainly related to cholesterol depletion from the organism. Onodera and
co-workers showed that folate-conjugated MβCD possessed an even higher antiproliferative activity
on solid tumors (IT and IV injections) [70] as well as on melanoma (subcutaneous administration,
SC) [58] with negligible side effects. The higher activity of these folate derivatives could be related
to the higher number of folate receptors expressed by cancer cells in comparison to healthy cells
(i.e., selectivity of action). Yokoo and coworkers showed that HPBCD also possessed antitumor action,
demonstrating cell growth inhibition and apoptosis in leukemic cells in vitro and in vivo [71].
6.3. Cyclodextrin Potentials in the Treatment of Degenerative Brain Disease
CDs have been investigated as possible treatment for Niemann-Pick type C (NPC) disease.
This syndrome is characterized by accumulation of esterified cholesterol and other lipids in cells,
predominantly in liver and central nervous systems. This uncontrolled accumulation causes irreversible
brain and liver damage that ultimately leads to death. Currently, no efficient medicine is available for
the treatment of NPC. IV administration of HPβCD to symptomatic Npc1−/− mice (standard animal
model for NPC) proved to sensibly delay the onset of neurological symptoms in the animals [72].
Later study showed that SC and IP administration of HPβCD to NPC diseased mice could reduce
neuronal cholesterol accumulation [73]. Interestingly, the life span of animals was prolonged to the
same extent as for miglustat administration (the only API approved for NPC treatment). Detailed
histological investigations also revealed a clear reduction in cholesterol accumulation in the most
sensitive organs of Npc1−/− mice (liver, spleen, and kidneys) after weekly administration of HPβCD
(SC injections) [74]. A similar study conducted by Tanaka et al. identified a significant increase in
life span of Npc1−/− of mice after daily SC administration of HPβCD [75]. In recent years, several
investigative new drug application documents for cyclodextrin treatment for Niemann Pick Type C
disease were filed [76] (and approved by FDA). Intravenous administration of HPβCD in human
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patients proved to be not so effective due to the moderate permeability of the pyranose derivatives
through the blood brain barrier (BBB) [77]. In this regard, intrathecal infusion of βCDs resulted in a
much more efficient administration pathway and, nowadays, several pharmaceutical trials employing
HPβCD for NPC on humans are currently underway in several countries [78].
Another extremely severe neurological disorder that is not treatable by current medicines
is Alzheimer Disease (AD). Yao and co-workers [79] proved that weekly subcutaneous injection
of HPβCD in mice model for AD (TG19959) could significantly improve memory deficits and
reduce β-amyloid peptide neuronal deposition. It was suggested that the reduction in β-amyloid
aggregation/deposition in the neurons could be related to alteration in cholesterol metabolism.
Subsequent studies have suggested that HPβCD probably interacts with β-amyloid peptide, reducing
its aggregation and deposition tendency [64]. Even though the mechanism of action is not completely
understood yet, HPβCD shows potential for the treatment of AD.
A summary of the cyclodextrins that have been investigated as possible active pharmaceutical
ingredients in vivo (and in humans) is reported in Table 2.
Table 2. Types of cyclodextrins that have been investigated as possible active pharmaceutical
ingredients in vivo (and in humans *).
Cyclodextrin Type Hypervitaminosis A Dyslipidemia and Atherosclerosis Chemotherapy NPC AD
βCD X
MβCD X X
HPβCD X * X X X * X
7. Conclusions
In the last three decades, cyclodextrin derivatives have shown tremendous potential for the
treatment for different diseases where available medicines in the market are failing to provide proper
treatment. Despite the promising results achieved in the last years, the interest of the pharmaceutical
community and industries in developing CDs as active pharmaceutical ingredients remain regrettably
low. As for the treatment of NPC, it is desirable that, cyclodextrins that are already approved from
American and European medical agencies could be promptly used in human trials to verify their
real potential as therapeutic agents. Moreover, the development of new CD types (e.g., polymeric
cyclodextrins) is to be encouraged, because it might lead to the discovery of the ultimate cure for
diseases such as atherosclerosis, cancer, and degenerative brain diseases that remain, at present, still of
poor treatability and considerable lethality.
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